We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+41.63%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.37B
AUM Growth
+$500M
Cap. Flow
+$109M
Cap. Flow %
4.61%
Top 10 Hldgs %
58.56%
Holding
56
New
7
Increased
13
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$31.4M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$23.8M
3
BBIO icon
BridgeBio Pharma
BBIO
+$23.5M
4
SLNO
Soleno Therapeutics
SLNO
+$18.6M
5
PEPG icon
PepGen
PEPG
+$17.7M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.1M
2
DYN icon
Dyne Therapeutics
DYN
+$15.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.1M
4
APGE icon
Apogee Therapeutics
APGE
+$11.2M
5
ETNB
89bio
ETNB
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.1B
$289M 12.2%
12,226,943
+95,238
+0.8% +$1.93M
KRYS icon
2
Krystal Biotech
KRYS
$10.4B
$176M 7.42%
988,460
– –
MIRM icon
3
Mirum Pharmaceuticals
MIRM
$5.94B
$163M 6.88%
6,495,392
– –
HLVX
4
DELISTED
HilleVax
HLVX
$163M 6.86%
9,781,472
– –
ALPN
5
DELISTED
Alpine Immune Sciences Inc
ALPN
$124M 5.24%
3,131,008
– –
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$743M
$107M 4.53%
10,109,279
– –
BBIO icon
7
BridgeBio Pharma
BBIO
$15B
$106M 4.46%
3,415,604
+689,655
+25% +$23.5M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.38B
$94.9M 4%
2,190,179
-181,125
-8% -$7.93M
ARQT icon
9
Arcutis Biotherapeutics
ARQT
$2.99B
$87.1M 3.67%
8,785,284
+21,052
+0.2% +$157K
PCVX icon
10
Vaxcyte
PCVX
$8.9B
$77.8M 3.28%
1,139,405
-25,000
-2% -$1.73M
TARS icon
11
Tarsus Pharmaceuticals
TARS
$3.15B
$65M 2.74%
1,787,527
– –
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.64B
$60.3M 2.54%
3,303,567
+636,364
+24% +$10.1M
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.37B
$57M 2.4%
4,142,855
+2,000,000
+93% +$23.8M
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$52M 2.2%
885,165
– –
IRON icon
15
Disc Medicine
IRON
$3.07B
$48.9M 2.06%
785,000
– –
VRNA
16
DELISTED
Verona Pharma
VRNA
$48.5M 2.05%
3,014,349
– –
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$43.7M 1.85%
3,687,867
+65,573
+2% +$874K
RCKT icon
18
Rocket Pharmaceuticals
RCKT
$424M
$42.1M 1.77%
1,561,230
+38,217
+3% +$1.09M
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
$37.5M 1.58%
875,667
+410,730
+88% +$18.6M
MGNX icon
20
MacroGenics
MGNX
$263M
$36.4M 1.54%
2,471,704
+70,000
+3% +$1.06M
JBIO
21
Jade Biosciences
JBIO
$1.33B
$35.6M 1.5%
34,425
– –
CGON icon
22
CG Oncology
CGON
$6.59B
$33.8M 1.43%
+770,000
New +$31.4M
MRUS
23
DELISTED
Merus
MRUS
$33.6M 1.42%
746,479
– –
RVMD icon
24
Revolution Medicines
RVMD
$44.6B
$32.1M 1.36%
997,455
– –
AUTL
25
Autolus Therapeutics
AUTL
$623M
$29.5M 1.24%
4,623,324
+876,467
+23% +$5.47M
1
2 3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2024 Portfolio in Review

As of Q1 2024, Frazier Life Sciences Management held 56 positions worth $2.37B, up 27% from $1.87B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Frazier Life Sciences Management deployed $109M of net new capital in Q1 2024, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was CG Oncology: 770,000 shares worth $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was 89bio, an estimated $11.1M trimmed.

  • Frazier Life Sciences Management's largest Q1 2024 buy was CG Oncology: 770,000 shares worth $33.8M.
  • Frazier Life Sciences Management added most to Oric Pharmaceuticals in Q1 2024, an estimated $23.8M increase.
  • Frazier Life Sciences Management's biggest Q1 2024 reduction was 89bio, cutting an estimated $11.1M.
  • Frazier Life Sciences Management fully exited Madrigal Pharmaceuticals in Q1 2024, selling an estimated $16.1M.
  • Frazier Life Sciences Management's ten largest holdings make up 59% of its $2.37B portfolio in Q1 2024.
  • Frazier Life Sciences Management opened 7 new positions and closed 6 in Q1 2024.
  • Frazier Life Sciences Management's portfolio value rose 27% quarter-over-quarter to $2.37B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2024, filed 15 May 2024.